Aura Biosciences (AURA) Income from Continuing Operations (2020 - 2026)
Aura Biosciences (AURA) posted Income from Continuing Operations of 33685000.0 for Q1 2026, down 142.28% on a QoQ basis from 79674000.0 in Q4 2025, and down 22.57% year-over-year from 43501943.28 in Q1 2025.
Aura Biosciences (AURA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Aura Biosciences' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 33685000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 22.57% year-over-year to 33685000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7160000.0 (up 92.52% YoY) and the FY2025 annual result came in at 958000.0, up 98.91% from the prior year.
- Income from Continuing Operations was 33685000.0 for Q1 2026 at Aura Biosciences, down from 79674000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 79674000.0 in Q4 2025 and bottomed at 74303000.0 in Q1 2022.
- A 5-year average of 23043529.41 and a median of 22131000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 1135.3% — and 2025, when it jumped 396.12%.
- Aura Biosciences' Income from Continuing Operations stood at 18381000.0 in 2022, then declined by 20.4% to 22131000.0 in 2023, then fell by 21.58% to 26906000.0 in 2024, then jumped by 396.12% to 79674000.0 in 2025, then plunged by 142.28% to 33685000.0 in 2026.
- Business Quant data shows AURA's Income from Continuing Operations at 33685000.0 in Q1 2026, 79674000.0 in Q4 2025, and 26130000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Aura Biosciences | 474.16 Mn | 389.36 Mn | - | -33.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.69 Mn |
| Dec 31, 2025 | 79.67 Mn |
| Sep 30, 2025 | -26.13 Mn |
| Jun 30, 2025 | -27.02 Mn |
| Mar 31, 2025 | -27.48 Mn |
| Dec 31, 2024 | -26.91 Mn |
| Sep 30, 2024 | -21.04 Mn |
| Jun 30, 2024 | -20.34 Mn |
| Mar 31, 2024 | -19.71 Mn |
| Dec 31, 2023 | -22.13 Mn |
| Sep 30, 2023 | -18.51 Mn |
| Jun 30, 2023 | -18.30 Mn |
| Mar 31, 2023 | -17.47 Mn |
| Dec 31, 2022 | -18.38 Mn |
| Sep 30, 2022 | -59.05 Mn |
| Jun 30, 2022 | -40.96 Mn |
| Mar 31, 2022 | -74.30 Mn |
| Dec 31, 2021 | -11.78 Mn |
| Sep 30, 2021 | -22.95 Mn |
| Jun 30, 2021 | -8.80 Mn |